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Condensation 
The beneficial effect of aspirin in the prevention of preterm preeclampsia appears 
to depend with compliance. 
 
Short version of article title 
Compliance with aspirin treatment determines efficacy in the reduction of 
preeclampsia 
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ABSTRACT 
Objective: To examine the influence of compliance on the beneficial effect of 
aspirin in prevention of preterm preeclampsia in the Combined Multimarker 
Screening and Randomized Patient Treatment with Aspirin for Evidence-Based 
Preeclampsia Prevention (ASPRE) trial. 
Study design: This was a secondary analysis of data from the ASPRE trial. In this 
multicenter-study women with singleton pregnancies had screening by means of 
an algorithm that combines maternal factors and biomarkers (mean arterial 
pressure, uterine-artery pulsatility index, and maternal serum 
pregnancy-associated plasma protein A and placental growth factor) at 11-13 
weeks’ gestation. Those with an estimated risk for preterm preeclampsia of >1 in 
100 were invited to participate in a double-blind trial of aspirin (150 mg per day) vs. 
placebo from 11 to 14 until 36 weeks’ gestation. Preterm preeclampsia with 
delivery at <37 weeks’ gestation, which was the primary outcome, occurred in 1.6% 
(13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the 
placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 
to 0.74). The proportion of prescribed tablets taken was used as an overall 
measure of compliance. Logistic-regression analysis was used to estimate the 
effect of aspirin on the incidence of preterm preeclampsia according to 
compliance of <90% and >90%, after adjustment for the estimated risk of preterm 
preeclampsia at screening and the participating center. The choice of cut-off of 
90% was based on an exploratory analysis of the treatment effect. Logistic 
regression analysis was used to investigate predictors of compliance >90% 
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among maternal characteristics and medical history. 
Results: Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin 
group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group 
with compliance <90%, in 22/588 (3.7%) of participants in the placebo group with 
compliance ≥90%, and in 13/234 (5.6%) of participants in the placebo group with 
compliance <90%. The odds ratio in the aspirin group for preterm preeclampsia 
was 0.24 (95% confidence interval, 0.09 to 0.65) for compliance >90% and 0.59 
(95% confidence interval, 0.23 to 1.53) for compliance <90%.  Compliance was 
positively associated with family history of preeclampsia and negatively 
associated with smoking, maternal age <25 years, Afro-Caribbean and South 
Asian racial origin, and history of preeclampsia in a previous pregnancy. 
Conclusions: The beneficial effect of aspirin in the prevention of preterm 
preeclampsia appears to depend on compliance. 
 
 
Key words: First trimester screening, Aspirin, ASPRE trial, Preeclampsia, 
Pyramid of pregnancy care, Compliance, Uterine artery Doppler, Mean arterial 
blood pressure, Placental growth factor, Pregnancy associated plasma protein-A, 
Prediction, Treatment effect. 
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Introduction 
Several trials have examined the potential value of aspirin in the prevention of 
preeclampsia (PE) in women at high-risk of developing this disease. These trials 
provided inconsistent results, possibly because of heterogeneity in entry criteria, 
gestational age at onset of treatment, dosage of aspirin and outcome measure 
being total-PE or preterm-PE with delivery at <37 weeks’ gestation.1,2 In the recent 
ASPRE trial (Combined Multimarker Screening and Randomized Patient 
Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) women with 
singleton pregnancies had screening by means of an algorithm that combines 
maternal factors, mean arterial pressure (MAP), uterine-artery pulsatility index 
(UTPI), and maternal serum pregnancy-associated plasma protein A (PAPP-A) 
and placental growth factor (PLGF) at 11-13 weeks’ gestation.3,4 Those with an 
estimated risk for preterm PE of >1 in 100 were invited to participate in a 
double-blind trial of aspirin (150 mg/day) vs. placebo from 11 to 14 until 36 weeks’ 
gestation. Preterm-PE, which was the primary outcome, occurred in 1.6% 
(13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the 
placebo group (odds ratio in the aspirin group with adjustment for the effect of the 
estimated risk for preterm-PE at screening and participating center 0.38; 95% 
confidence interval, 0.20 to 0.74).3 The trial showed that aspirin had no significant 
effect in reducing the risk of term-PE.  
 Extensive evidence suggests that in many medical conditions patients who 
are compliant with drug therapy have better outcomes than those with poor 
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compliance and in randomized trials the results could be influenced by the level of 
compliance.5-11 
The objectives of this study, which is a secondary analysis of data from the 
ASPRE trial, are to examine the factors affecting compliance and the influence of 
compliance on the beneficial effect of aspirin in prevention of preterm-PE. 
 
Methods 
Study population 
This was a prospective, multicenter study in consecutive singleton pregnancies at 
11+0 -13+6 weeks’ gestation in women booking for routine pregnancy care at 13 
maternity hospitals in the United Kingdom, Spain, Italy, Belgium, Greece, and 
Israel.3 Maternal demographic characteristics and medical and obstetric history 
were recorded,12 MAP was measured by validated automated devices and 
standardized protocol,13 transabdominal color Doppler ultrasound was used to 
measure the left and right UTPI and the average value was recorded,14 serum 
PAPP-A and PLGF concentrations were measured by an automated device 
(PAPP-A and PlGF 1-2-3TM kits, DELFIA® Xpress random access platform; 
PerkinElmer Inc. Wallac Oy, P.O.Box 10, 20101 Turku, Finland). All operators 
undertaking the Doppler studies had received the appropriate Certificate of 
Competence from the Fetal Medicine Foundation. Measured values of MAP, UTPI, 
PAPP-A and PLGF were expressed as a MoM adjusting for those characteristics 
found to provide a substantive contribution to the log10 transformed value 
including the maternal factors in the prior model.15-18 Gestational age was 
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determined from the measurement of fetal crown-rump length.19 The 
patient-specific risk for preterm-PE was estimated from a combination of maternal 
factors and biomarkers.4 
The eligibility criteria were maternal age >18 years, no serious mental illness 
or learning difficulties, singleton pregnancy with live fetus with no major 
abnormality demonstrated on the 11-13 weeks scan. Eligible women with an 
estimated risk for preterm-PE of >1 in 100 were invited to participate in a 
double-blind trial of aspirin (150 mg per day) vs. placebo from 11 to 14 until 36 
weeks’ gestation.3 The placebo tablets were identical to the aspirin tablets with 
respect to variables such as size, thickness, physical properties, and appearance. 
Approval for the trial was obtained from the relevant research ethics committee 
and competent authority in each country in which the trial was conducted. 
 
Primary outcome 
The primary outcome measure was delivery with PE at <37 weeks’ gestation. 
Preeclampsia was defined according to the International Society for the Study of 
Hypertension in Pregnancy.20 The systolic blood pressure should be >140 mmHg 
and/or the diastolic blood pressure should be >90 mmHg on at least two 
occasions four hours apart developing after 20 weeks of gestation in previously 
normotensive women. Hypertension should be accompanied by proteinuria of 
>300 mg in 24 hours or two readings of at least ++ on dipstick analysis of 
midstream or catheter urine specimens if no 24-hour collection is available. In PE 
superimposed on chronic hypertension significant proteinuria (as defined above) 
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should develop after 20 weeks of gestation in women with known chronic 
hypertension. 
 
Compliance 
We assessed compliance by counting the tablets that were returned by 
participants at each visit and by the participants’ reporting of tablet counts during 
each telephone interview. The total number of tablets taken was calculated by 
subtracting the number of tablets returned from the number of tablets prescribed. 
Compliance was calculated as a percentage of the reported intake of tablets to 
the total number that participants were expected to have taken between the date 
of randomization and the date of the visit at 36 weeks’ gestation or the date of 
delivery if delivery occurred before 36 weeks. 
 
Statistical analyses 
Logistic-regression analysis was used to test the difference in the incidence of 
preterm-PE between the aspirin and placebo groups. The estimated risk of 
preterm-PE at screening and the participating center were included as covariates. 
The treatment effect was quantified as the odds ratio (aspirin/placebo) with a 95% 
confidence interval (CI). We analysed the aspirin effects in subgroups with 
compliance cut-offs of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, and 
95%. On the basis of these analyses we chose to dichotomise compliance using a 
cut-off of 90%. Logistic regression analysis was used to estimate the effect of 
aspirin on the incidence of preterm-PE stratified according to compliance of <90% 
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and >90%, adjusting for the estimated risk of preterm-PE at screening and the 
participating center.  
Logistic regression analysis was used to quantify predictors of compliance 
>90% among maternal characteristics and medical history (age, body mass index, 
method of conception, racial origin, smoking, family history of PE, parity with and 
without previous PE, medical history of chronic hypertension, diabetes mellitus, 
systemic lupus erythematosus or antiphospholipid syndrome). 
The statistical software package R was used for data analyses.21  
 
Results  
There were no significant differences between the aspirin and placebo groups 
with regard to the characteristics of the participants at baseline.3 Preterm-PE 
occurred in 13 of 798 participants (1.6%) in the aspirin group, as compared with 
35 of 822 (4.3%) in the placebo group (adjusted odds ratio in the aspirin group, 
0.38; 95% confidence interval, 0.20 to 0.74; P = 0.004).3 The size of the treatment 
effect was consistent across estimated risk groups at the time of screening, 
across groups defined according to obstetrical history, and across countries of the 
participating centers.3 
Compliance, as pre specified in the trial protocol, was considered to be good if 
it was >85%, moderate if 50-84.9% and poor if <50% and according to the results 
it was good in 80% of participants, moderate in 15% and poor in 5%.3 The results 
of subgroup analysis on the aspirin effects according to different compliance 
cut-offs are shown in Figure 1. The aspirin effect was substantially increased in 
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the subgroup of compliance of >90% with no further increase in the >95% 
compliance subgroup. We dichotomized compliance using a cut-off of 90%. After 
adjustment for the estimated risk of preterm-PE at screening and the participating 
center, both aspirin (odds ratio 0.37, 95% CI 0.19 to 0.72) and compliance (odds 
ratio 0.49, 95% CI 0.27 to 0.91) were independent predictors of preterm-PE. 
Although the interaction between treatment and compliance was not statistically 
significant (P = 0.19), the estimated aspirin effect was smaller with compliance 
<90% than with compliance ≥90% (Figure 2). 
Logistic regression analysis demonstrated that compliance >90% was 
positively associated with family history of PE and negatively associated with 
smoking, maternal age <25 years, Afro-Caribbean and South Asian racial origin, 
and multiparity with history of PE in a previous pregnancy; there were no 
significant effects of body mass index, method of conception, multiparity with no 
PE in a previous pregnancy or history of pre-existing medical condition (Figure 3). 
 
Comment 
Principal findings of this study 
The ASPRE trial demonstrated that, in women with singleton pregnancies 
identified by means of first trimester screening as being at high risk for 
preterm-PE, the administration of aspirin at a dose of 150 mg per day from 11 to 
14 weeks until 36 weeks’ gestation reduces the incidence of preterm-PE by 
approximately 60%.3 The results of the secondary analysis suggest that the 
beneficial effect of aspirin depends on compliance and the reduction in incidence 
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of preterm-PE may be about 75% in those with compliance of >90% and only 40% 
in those with compliance of <90%. The trial was powered for a 50% reduction in 
the incidence of preterm-PE and had the overall compliance been <90% the trial 
may have failed to demonstrate a significant benefit of aspirin in reducing the 
incidence of preterm PE.   
High compliance was positively associated with family history of PE and 
negatively associated with smoking, maternal age <25 years, Afro-Caribbean and 
South Asian racial origin, and multiparity with history of PE in a previous 
pregnancy. A possible explanation for the surprising finding of low compliance in 
those with previous history of PE is that poor compliance is associated with an 
unknown trait that is also associated with PE. A good example of such a trait that 
we know about is Afro-Caribbean racial origin which is associated with poor 
compliance and with increased risk for PE.12 Consequently, the observed 
dependence of the beneficial effect of aspirin on compliance may at least in part 
be due to differences in the characteristics of the highly compliant subjects 
compared to those with lower compliance. 
 
Limitations of the study 
The data of this study suggest that the beneficial effect of aspirin in the prevention 
of preterm-PE, demonstrated in the ASPRE trial,3 is dependent on compliance, 
but the trial was not adequately powered for such secondary analysis. Another 
limitation of the study relates to the method of ascertainment of compliance which 
relied on the counting of tablets rather than a more objective measurement of 
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biomarkers. There is a wide range of platelet activation and function assays that 
have been used to assess responsiveness to aspirin, but these assays suffer from 
limited reproducibility and poor agreement between them; additionally, suboptimal 
suppression of platelet activation does not necessarily reflect poor compliance but 
may be the consequence of interacting physiological, pharmacokinetic and 
pharmacodynamics factors.22 
 
Clinical implications of the study 
In clinical practice the importance of compliance to therapy is widely appreciated 
for healthcare outcomes but in the case of clinical trials regulators have been 
reluctant to acknowledge its importance, often hiding behind the use of 
intention-to-treat analysis of data which masks the problem.23 In the ASPRE trial if 
the compliance was <90% the effect of aspirin in reducing the incidence of 
preterm-PE may not have achieved significance. High compliance is an essential 
prerequisite of a successful clinical trial and poor compliance could lead to the 
erroneous conclusion that effective therapy may be ineffective. 
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Figure legends 
 
Figure 1. Odds ratio for preterm preeclampsia in the aspirin group with 95% 
confidence intervals in different subgroups according to compliance expressed as 
percentage of intake of the required number of tablets. 
 
Figure 2. Odds ratio for preterm preeclampsia in the aspirin group with 95% 
confidence intervals in the total population and the subgroups with compliance of 
<90% and >90%.  
 
Figure 3. Effect of maternal characteristics and obstetric and medical history on 
compliance of >90%. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
